Instrument Inactif

Autres langues Mount Magnet South Ltd Australian S.E.

Actions

AU000000MUM1

Recherche biotechnologique et médicale

Cours en clôture Australian S.E.
- ^AUD	-

25/09	Incannex Healthcare Inc. publie ses résultats pour l’exercice clos le 30 juin 2026	CI
09/09	Incannex Healthcare débute le dosage des patients dans l'étude de Phase 2 DReAMzz sur l'IHL-42X et fait état de ses progrès cliniques	CI

Autres langues

25/09	Incannex Healthcare Inc. Reports Earnings Results for the Full Year Ended June 30, 2026
09/09	Incannex Healthcare Commences Patient Dosing in DReAMzz Phase 2 Study Of IHL-42X and Reports Clinical Progress
09/09	Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
25/08	Incannex Healthcare Doses First Patient In DReAMzz Phase 2 Study Of IHL-42X
25/08	Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
11/08	Incannex Healthcare Receives Additional AUD 5.1 Million R&D Tax Incentive Refund, Completing More Than AUD 11.2 Million In Non-Dilutive Capital Received In 2026
11/08	Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026
23/07	Incannex Healthcare Inc. Commences Participant Screening In Dreamzz Phase 2 Study Of IHL-42X For Obstructive Sleep Apnea
23/07	Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
25/06	Incannex Healthcare Inc Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
25/06	Incannex Healthcare Receives US Patent for IHL-42X in Obstructive Sleep Apnea
25/06	Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
10/06	Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
09/06	Incannex Announces Initiation of Research Coverage by Alliance Global Partners
15/05	Tranche Update on Incannex Healthcare Inc.'s Equity Buyback Plan announced on August 22, 2025.
15/05	Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026
14/05	Incannex Healthcare commences Dreamzz clinical study of IHL-42X for obstructive sleep apnea
14/05	Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
14/05	Incannex Healthcare Inc Commences DReAMzz Clinical Study For IHL-42X In Obstructive Sleep Apnea
12/05	Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
22/04	Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
22/04	Incannex Healthcare Inc. Announces Incannex?s Completed Phase 2 Clinical Trial, PSX-001 Demonstrated Statistically Significant and Clinically Meaningful Improvements Across All Primary and Secondary Endpoints
27/03	Incannex reactivates share repurchase program, underscoring confidence in valuation and strategic position
27/03	Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
25/03	Incannex Healthcare Inc. Enters Partnership Agreement with American Academy of Sleep Medicine Foundation